LeMaitre Vascular stock reports a Q2 revenue miss

Published on 09/24/2026 at 15:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LeMaitre Vascular stock generated USD 70.38 million in Q2 2026, up 9.6 percent year over year. Adjusted EPS reached USD 0.74 versus USD 0.81 consensus.

LeMaitre Vascular stock, healthcare, medical instruments, Q2 earnings, revenue miss, Nasdaq, Illustration mit AI erstellt.

LeMaitre Vascular stock (ISIN US5255582018) stood at USD 80.58 on Nasdaq on September 23, 2026, while the company reported Q2 2026 revenue of USD 70.38 million. Revenue increased 9.6 percent year over year, but the quarterly result missed analyst expectations.

Revenue grows but misses estimates

According to Investing.com, LeMaitre reported adjusted earnings of USD 0.74 per share for Q2 2026, below the USD 0.81 consensus estimate. Revenue of USD 70.38 million also fell short of the USD 71.47 million forecast, a shortfall of 1.5 percent.

The earnings gap was wider than the sales gap. Adjusted EPS came in 8.6 percent below consensus, even as revenue growth remained positive and the company earned USD 0.60 per share in the comparable quarter of 2025.

Guidance sets the next test

Company guidance cited by Simply Wall St calls for Q3 2026 sales of USD 66.3 million to USD 68.3 million and adjusted EPS of USD 0.66 to USD 0.71. Full-year sales guidance stands at USD 274.3 million to USD 278.3 million, with adjusted EPS of USD 2.84 to USD 2.94.

That range makes execution the central issue for the stock. LeMaitre needs to convert its 9.6 percent Q2 revenue growth into results near the upper end of the annual outlook after the latest sales and EPS miss.

Stock remains below its yearly high

The Nasdaq share price of USD 80.58 on September 23, 2026, was down 0.49 percent from the previous session. The 52-week range was USD 78.22 to USD 118.01, placing the stock USD 37.43 below its yearly high, while market capitalization stood at USD 1,841,309,406.

LeMaitre Vascular develops devices and implants for peripheral vascular disease. The company also declared a quarterly dividend of USD 0.25, equivalent to USD 1.00 annually, according to MarketBeat.

USD 80.58 marks the reference price

LeMaitre Vascular stock stood at USD 80.58 on Nasdaq on September 23, 2026, with the latest quarterly figures and full-year guidance now framing the valuation discussion.